Updated Jul 16, 2026
Smith Hunter C has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $8.31M.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-20 | RYTM | RHYTHM PHARMACEUTICALS, INC. | M — Option exercise | 3.0K | $17.87 | $54K |
| 2026-03-03 | RYTM | RHYTHM PHARMACEUTICALS, INC. | M — Option exercise | 6.1K | $6.80 | $41K |
| 2026-02-20 | RYTM | RHYTHM PHARMACEUTICALS, INC. | S — Open-market sale [10b5-1] | 585 | $103.28 | $60K |
| 2026-02-20 | RYTM | RHYTHM PHARMACEUTICALS, INC. | S — Open-market sale [10b5-1] | 800 | $102.10 | $82K |
| 2026-02-20 | RYTM | RHYTHM PHARMACEUTICALS, INC. | S — Open-market sale [10b5-1] | 1.7K | $100.92 | $171K |
| 2026-02-20 | RYTM | RHYTHM PHARMACEUTICALS, INC. | S — Open-market sale [10b5-1] | 1.3K | $100.27 | $131K |
| 2026-02-20 | RYTM | RHYTHM PHARMACEUTICALS, INC. | S — Open-market sale [10b5-1] | 200 | $103.84 | $21K |
| 2026-02-20 | RYTM | RHYTHM PHARMACEUTICALS, INC. | S — Open-market sale [10b5-1] | 1.1K | $103.00 | $110K |
| 2026-02-20 | RYTM | RHYTHM PHARMACEUTICALS, INC. | S — Open-market sale [10b5-1] | 900 | $101.70 | $92K |
| 2026-02-20 | RYTM | RHYTHM PHARMACEUTICALS, INC. | S — Open-market sale [10b5-1] | 200 | $100.52 | $20K |
| 2026-02-20 | RYTM | RHYTHM PHARMACEUTICALS, INC. | S — Open-market sale [10b5-1] | 1.2K | $99.42 | $119K |
| 2026-02-13 | RYTM | RHYTHM PHARMACEUTICALS, INC. | S — Open-market sale [10b5-1] | 100 | $100.10 | $10K |
| 2026-02-13 | RYTM | RHYTHM PHARMACEUTICALS, INC. | S — Open-market sale [10b5-1] | 800 | $98.99 | $79K |
| 2026-02-13 | RYTM | RHYTHM PHARMACEUTICALS, INC. | S — Open-market sale [10b5-1] | 400 | $97.67 | $39K |
| 2026-02-13 | RYTM | RHYTHM PHARMACEUTICALS, INC. | S — Open-market sale [10b5-1] | 292 | $96.26 | $28K |
| 2026-02-13 | RYTM | RHYTHM PHARMACEUTICALS, INC. | S — Open-market sale [10b5-1] | 100 | $100.85 | $10K |
| 2026-02-13 | RYTM | RHYTHM PHARMACEUTICALS, INC. | S — Open-market sale [10b5-1] | 400 | $99.44 | $40K |
| 2026-02-13 | RYTM | RHYTHM PHARMACEUTICALS, INC. | S — Open-market sale [10b5-1] | 2.3K | $98.37 | $223K |
| 2026-02-13 | RYTM | RHYTHM PHARMACEUTICALS, INC. | S — Open-market sale [10b5-1] | 100 | $104.76 | $10K |
| 2026-02-13 | RYTM | RHYTHM PHARMACEUTICALS, INC. | S — Open-market sale [10b5-1] | 700 | $103.68 | $73K |
Smith Hunter C is a corporate insider — currently tracked as Chief Financial Officer of RHYTHM PHARMACEUTICALS, INC. (RYTM). InsiderAlpha tracks every SEC Form 4 filing in real time.
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 28 open-market sales ($8.31M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Smith Hunter C profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.